Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC161-DP0292 is an **aqueous oral spray saliva substitute** developed as a treatment for **drug-induced xerostomia** (dry mouth) in adults with hyposalivation. Its mechanism is based on **mechanical and physicochemical lubrication** of the oral mucosa, acting as an artificial saliva to relieve symptoms such as mouth dryness, difficulty swallowing, and speaking. The formulation includes **glycerol, povidone K30, xanthan gum, potassium chloride, xylitol, potassium dihydrogen phosphate, benzylic alcohol, water, and macroglycerol 40 hydroxystearate**. Clinical studies show it provides **fast and long-acting symptomatic relief** and is well-tolerated, with high acceptability for taste, texture, and lubricating effect compared to comparator sprays. It does not act via a pharmacological receptor or enzyme, but recreates the physical actions of saliva, making it a symptomatic, not disease-modifying, therapy[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DC161-DP0292.